Rhenman & Partners Asset Management’s Abeona Therapeutics ABEO Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-37,000	Closed	-$944K	–	84
2020 Q3	$944K	Hold	37,000	–	–	0.08%	78
2020 Q2	$2.7M	Sell	37,000 -1,000	-3%	-$69.1K	0.29%	77
2020 Q1	$2M	Sell	38,000 -2,000	-5%	-$134K	0.28%	76
2019 Q4	$3.27M	Hold	40,000	–	–	0.36%	75
2019 Q3	$2.26M	Buy	40,000 +14,035	+54%	+$1.05M	0.28%	73
2019 Q2	$3.1M	Hold	25,965	–	–	0.34%	66
2019 Q1	$4.78M	Hold	25,965	–	–	0.56%	60
2018 Q4	$4.63M	Buy	+25,965	New	+$5.66M	0.53%	59

Other funds holding ABEO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rhenman & Partners Asset Management's ABEO Position: Q4 2020 in Review

Rhenman & Partners Asset Management sold out of Abeona Therapeutics (ABEO) in Q4 2020, closing a stake of 37,000 shares — an estimated $944K sold.

Rhenman & Partners Asset Management first reported a position in ABEO in Q4 2018 and held it in 8 quarters. The position peaked at $4.78M in Q1 2019. 73 funds tracked by Wall St. Rank hold ABEO as of Q4 2020.

Rhenman & Partners Asset Management reported no remaining Abeona Therapeutics position as of Q4 2020 after selling out during the quarter.
Rhenman & Partners Asset Management sold 37,000 Abeona Therapeutics shares in Q4 2020, an estimated $944K.
Rhenman & Partners Asset Management first reported a position in Abeona Therapeutics in Q4 2018 and held it in 8 quarters.
Rhenman & Partners Asset Management's Abeona Therapeutics position peaked at $4.78M in Q1 2019.
73 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2020.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2020, filed 19 Jan 2021.